Biohaven's troriluzole candidate for spinocerebellar ataxia (SCA) has been turned down by the FDA, causing shares in the company to lose more than 40% of their value in pre-market trading. The news is ...
Spinocerebellar ataxia type 1 (SCA1) is an inherited neurodegenerative disease involving progressive loss of motor and cognitive function resulting from the death of cerebellar neurons. Watase et al.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback